R289 is displaying good tolerance with elderly lower-risk MDS patients who have undergone extensive prior treatment. Preliminary efficacy has been noted at doses of 500 mg or higher once a day, where 33% (6 out of 18) of transfusion-dependent patients achieved RBC-TI. This success rate increased to 40%...